top of page

Global Regulatory Toxicology Consulting

Let's chat about your project

Search

Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promote

jeanfrancoismaison
May 16
1 min read

https://pubmed.ncbi.nlm.nih.gov/40360436/

Recent Posts

Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in children aged 10-12 years: phase III randomized trial complementary analysis of immune persistence 3-6 years after priming

https://pubmed.ncbi.nlm.nih.gov/39672823/

Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSV

https://pubmed.ncbi.nlm.nih.gov/40245915/

Multi-criteria decision making and its application to in silico discovery of vaccine candidates for Toxoplasma gondii

https://pubmed.ncbi.nlm.nih.gov/40378548/

bottom of page